RxDoctor Payments DataLook up a doctor →

Lance Pagliaro, MD

Medical Oncology · Rochester, MNNPI 1568553311

Payments from drug & device makers

$5,092,393in general payments, 2019–2025

Across 323 payments — averaging $15,766 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.1M
  • Astellas US Technologies$1.3M
  • Exelixis Inc.$1M
  • Astellas Pharma Global Development$516K
  • Merck$120K
  • Regeneron$37K
  • plus $23K from 1 others

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer74$2,140,766
Astellas US Technologies11$1,250,834
Exelixis Inc.177$1,004,346
Astellas Pharma Global Development12$515,784
Merck40$120,421
Regeneron4$36,860
F. Hoffmann-la Roche AG5$23,383

How this compares

$5,092,393 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$995,170
Medicare patients
271
Services billed
33,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →